Board of Directors

Board of directors
The Board of Directors of the Albert and Mary Lasker Foundation
Standing, left to right: Willard Overlock, Russell Steenberg, Sherry Lansing, Anthony Evnin, Marshall Fordyce, John Considine, Jordan Gutterman, Christopher Brody. Seated, left to right: George Roche, Robert Tjian, Barbara Barrett, Alfred Sommer, Claire Pomeroy, Joseph Goldstein, Solomon Snyder. Not pictured: Chris Jones, George Noon, Elias Zerhouni.

Willard J. Overlock, Jr.
Chair
Willard "Mike" Overlock joined Goldman, Sachs & Co. in 1973 and was elected to the partnership in 1982. He headed the Mergers & Acquisitions Department from 1985 to 1996 and served as co-head of Investment Banking from 1990 to 1996. He served on the Management Committee and was a member of the International Executive Committee from 1990 to 1995. He became a Limited Partner in 1996 and a Senior Director in 1999. Overlock joined the Board of Directors of the Lasker Foundation in 2010 and became Chair of its board in 2014. Overlock is a director of Becton, Dickinson & Co. and an adviser to The Parthenon Group in Boston. He is a Special Partner at Cue Ball Capital. He serves as a trustee of The Rockefeller University and is a member of the Board of Overseers at Columbia Graduate School of Business. Overlock is a former Chair of the Board and board member of the Juvenile Diabetes Research Foundation International from 1992-1998. Overlock received a BA in economics from the University of North Carolina in 1968 and an MBA from Columbia Business School in 1973. He served in the U.S. Army as a first lieutenant in Vietnam from 1970 to 1971. He and his spouse, Trina, have three children.

Claire Pomeroy, MD, MBA
President
Claire Pomeroy is president of the Albert and Mary Lasker Foundation. She serves as chief executive officer of the Foundation and is responsible for overseeing the implementation of programs which advance the Foundation's mission to "improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy." An expert in infectious diseases, Pomeroy is a long-time advocate for patients, especially those with HIV/AIDS, and public health. She passionately supports ongoing investment in the full range of research. She continues to lead an active research team studying host responses to viral infections. She has a special interest in health care policy, with a focus on the importance of the social determinants of health. She has published more than 100 articles and book chapters and has edited three books. Pomeroy is a member of the Board of Trustees for the Morehouse School of Medicine and serves on the Board of Directors for the Sierra Health Foundation; the Foundation for Biomedical Research; and PRIDE Industries. She is co-chair of the Blue Ridge Academic Health group and serves on the VA National Academic Affiliations Council. She is a member of the Board of Directors of Expanesthetics, Inc. and of Becton, Dickinson and Company. Past roles include chair of the Board of Directors for the Association of Academic Health Care Centers (AAHC) and chair of the Council of Deans and Board member of the Association of American Medical Colleges (AAMC). She was elected in 2011 as member-at-large-representative for the AAAS medical sciences section. Pomeroy was inducted into the Institute of Medicine in 2011. Pomeroy received bachelors and medical degrees from the University of Michigan and completed her residency and fellowship training in internal medicine and infectious diseases at the University of Minnesota. She earned an MBA from the University of Kentucky. She has held faculty positions at the University of Minnesota, University of Kentucky and University of California (UC) Davis; she is currently professor emerita at UC Davis. Pomeroy was chief of infectious diseases and associate dean for research and informatics at the University of Kentucky. She joined UC Davis in 2003 as executive associate dean and in 2005 was appointed CEO and vice chancellor of the Health System and dean of the School of Medicine. She became president of the Albert and Mary Lasker Foundation in June 2013.

John R. Considine
Secretary and Treasurer
John Considine retired as Vice Chairman of BD (Becton, Dickinson and Company) in 2010. BD is a global medical technology company which manufactures and sells a broad range of medical devises, laboratory equipment and diagnostic products. Considine joined BD as Executive Vice President and Chief Financial Officer in June 2000 from Wyeth (formerly American Home Products), where he was Senior Vice President, Finance. In addition to his role as CFO, he had responsible for Integrated Supply Chain; Information Technology; Environment, Health and Safety; Project Management and Engineering Services; and Security. He was elected to BD's Board of Directors as Vice Chairman in March 2008 and held the CFO position through November 2008. During his 17 years at Wyeth, Considine served in various financial management positions, including leading the company's controllership, treasury, investor relations and internal audit groups. He was a member of the Wyeth finance, retirement and operations committees and a member of the Board of Directors of Immunex, Wyeth's then majority-owned biopharmaceutical subsidiary. Prior to joining Wyeth, Considine was with Arthur Andersen & Company for 10 years. Considine is a past member of the Board of Trustees of Fairfield Preparatory College and the Board of Directors of St. Joseph's Hospital and Medical Center in Paterson, New Jersey. He is a founding member of the Animal Cancer Foundation, an honorary board member of St. Vincent's Services and serves as President of the Board of Governors of Woodway Country Club. Considine has been a member of the Board of Directors of the Albert and Mary Lasker Foundation since 2008.

Ambassador Barbara Barrett
Barbara Barrett is Chairman of the Aerospace Corporation, and a member of the governing boards of California Institute of Technology, RAND Corporation, Smithsonian Institution, Sally Ride Science and Horatio Alger Association. Previously, Barrett was U.S. Ambassador to Finland, Interim President of Thunderbird School of Global Management, Senior Advisor to the U.S. Mission to the UN, a Fellow teaching Leadership at Harvard University, CEO of the American Management Association, Founding Chairman of Valley Bank of Arizona, Deputy Administrator of the Federal Aviation Administration and Vice Chairman of the U.S. Civil Aeronautics Board. An instructor and frequent speaker on corporate governance topics, she also served on the boards of Mayo Clinic, Good Samaritan Health (now Banner Health), Arizona Disease Control Research Commission, Palms Clinic and Hospital Corporation, medical imaging technology producer Ultrasight, National Association of Corporate Directors, Hershey, Exponent, Raytheon and Space Foundation. She was a partner in a Phoenix law firm and an executive of two global Fortune 500 companies. She and her husband, Craig, own Triple Creek Guest Ranch in Montana. An instrument rated pilot, she was reportedly the first civilian woman to land in an F/A-18 on an aircraft carrier and trained at the Gagarin Cosmonaut Training Center in Russia, culminating in certification as an astronaut. Barrett joined the Lasker Foundation's Board of Directors in 2012.

Christopher W. Brody
Christopher W. Brody is Chairman of Vantage Partners, LLC, a private investment partnership. From 1972 to 1998, Brody was a Partner of Warburg, Pincus, and, for over 15 years, served as a member of its Operating Committee which managed the private equity and venture capital activities of the firm. He is currently a member of the Board of Directors of Intuit Inc., and several privately held companies. Brody is also a member of the Boards of the Mount Sinai Medical Center and the Mount Sinai School of Medicine, and is also a member of the Council on Foreign Relations. His past boards have included Claremont University and Graduate Center and the United Nations Association. He is a former Chairman of the National Venture Capital Association, and in 1999, became the first recipient of its Outstanding Service Award. He received a B.A. in English Literature in 1966 from Harvard College and received an MBA in 1968 from Harvard Business School. Brody has been a member of the Board of Directors of the Albert and Mary Lasker Foundation since 1975.

Anthony Evnin, PhD
Tony Evnin joined Venrock in 1974 and built the firm's healthcare franchise, helping to shape the modern biotechnology industry. Evnin is focused on building valuable companies that address important medical needs of the world, while providing strong returns for investors. He currently serves on the Board of Directors of two public companies, including AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI), as well as two private Boards. Past investments include Centocor (IPO/ acquired by Johnson & Johnson), Coley Pharmaceutical Group (IPO/ acquired by Pfizer), Genetics Institute (IPO/ acquired by Wyeth), Icagen (IPO/ acquired by Pfizer), IDEC Pharmaceuticals (IPO/ merged with Biogen), IDEXX Laboratories (NASDAQ: IDXX), Millennium Pharmaceuticals (IPO/ acquired by Takeda) and Sepracor (IPO/ acquired by Dainippon Sumitomo). More than 30 of his investments have been through an IPO during his Venrock tenure. Evnin started his career as a Research Scientist and Group Leader in Organic Chemistry at Union Carbide and as Director of Product Development at Story Chemical. He serves as a Trustee of The Rockefeller University, as a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, as Trustee of The Jackson Laboratory, and as a Trustee Emeritus of Princeton University. Evnin received his A.B. in Chemistry from Princeton University and his Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Marshall W. Fordyce, MD
Marshall Fordyce is Director of Clinical Research at Gilead Sciences, where his current research focuses on the development of novel tenofovir prodrugs for the treatment of HIV infection. Previously, Fordyce was Instructor in Clinical Medicine and Clinical Scholar at The Rockefeller University, and Research Fellow at the Aaron Diamond AIDS Research Center, where under Dr. David Ho, his research focused on the effect of the HIV entry inhibitor, ibalizumab, on the envelope protein, and the immunologic effects of initiating antiretroviral therapy during acute infection. Fordyce received his Bachelor's degree and MD from Harvard University. He completed his Internal Medicine Training at New York University/Bellevue Hospital, where he served as Senior Chief Resident, and completed his Infectious Disease training at Columbia Presbyterian Hospital. Fordyce is also board certified in Internal Medicine and Infectious Diseases. Fordyce became a member of the Board of Directors of the Albert and Mary Lasker Foundation in 2012.

Joseph L. Goldstein, MD
Joseph L. Goldstein, M.D. is currently Chairman of the Department of Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas. He is the Regental Professor of the University of Texas. He also holds the Paul J. Thomas Chair in Medicine and the Julie and Louis A. Beecherl Distinguished Chair in Biomedical Science. Goldstein and his colleague, Michael S. Brown, discovered the low density lipoprotein (LDL) receptor and worked out how these receptors control cholesterol homeostasis. At the basic level, this work opened the field of receptor-mediated endocytosis, and at the clinical level it helped lay the conceptual groundwork for development of drugs called statins that lower blood LDL-cholesterol and prevent heart attacks. Goldstein and Brown shared many awards for this work, including the Lasker Award in Basic Medical Research (1985), Nobel Prize in Physiology or Medicine (1985), and National Medal of Science (1988). In recent work, Goldstein and Brown discovered the SREBP family of transcription factors and showed how these membrane-bound molecules control the synthesis of cholesterol and fatty acids through a newly described process of Regulated Intramembrane Proteolysis. For this work, Brown and Goldstein received the Albany Medical Center Prize in Medicine and Biomedical Research (2003). Goldstein is a member of the Boards of Trustees of the Howard Hughes Medical Institute and The Rockefeller University. He also serves on the Scientific Advisory Boards of the Welch Foundation, Memorial Sloan-Kettering Cancer Center, and the Broad Institute. He is a member of the U.S. National Academy of Sciences and a Foreign Member of the Royal Society. Goldstein has been a member of the Board of Directors of the Albert and Mary Lasker Foundation since 2007, and currently serves as Chairman of the Lasker Medical Research Awards Jury.

Jordan U. Gutterman, MD
Jordan U. Gutterman is the Virginia H. Cockrell Professor of Immunology and Professor of Medicine at the University of Texas MD Anderson Cancer Center. Gutterman currently serves on the Scientific Advisory Council for the Cancer Research Institute and has served on numerous committees and scientific advisory boards, including Institute of Medicine Committee on FDA Advisory Committees, the FDA Advisory Committee on Biological Response Modifiers, the Alliance for Aging Research Scientific Advisory Board, and as Co-chairman of the American Cancer Society Interferon Committee. He is a member of many distinguished scientific societies including the American Medical Association, the American College of Physicians, the American Society for Microbiology, and the American Association for Cancer Research. Gutterman received his Bachelor of Arts degree from the University of Virginia and his medical degree from the Medical College of Virginia. Gutterman has been involved extensively with the Albert and Mary Lasker Foundation since 1978. He served as a Member of the Albert Lasker Medical Research Awards Jury between 1978 and 1989, and as a Member of the Board of Directors since 1983, for which he currently serves as the Board's Representative to the Lasker Medical Research Jury.

Chris Jones
After graduating from Cambridge University, Chris spent 24 years in the advertising industry during which time he became the worldwide Chairman and Chief Executive Officer of J Walter Thompson Co, one of the world's biggest international advertising groups. He was the youngest person and first non-American to hold this position in the company's 140-year history. In 2001, after a serious illness, Chris retired from the advertising business. He left New York City in 2002 and returned to live in England. Based in the UK in the past decade, Chris has developed an extensive range of business and not-for-profit interests around the world: In Financial Services, Jones is an outside member of the Partner Board at Motion Equity Partners. He was a non-executive director of Central Trust plc from 2008-2011. He is the Chairman of Results International, and Chairman of the Richmond Group. In Healthcare, Jones is a member of the Board of Becton Dickinson and Co. He was the Senior Independent Director of Xenogen Inc of Alameda California from 2001 through its flotation in 2004 till its acquisition by Caliper in 2006. He is Chairman of the Pavilion Clinic and is an adviser to the Oxford Musculo-Skeletal Clinic. In Technology, Jones is Chairman of the Board of Freedom Holdings. He has been an advisory board member and investor at Webs Inc which was acquired by Vistaprint NV in 2012. He is an advisor to Nardello and Co. In not-for-profit, Jones is the Chairman of the Governors at the Dragon School, Oxford and Chairman of the Finance Committee at St Edward's School. He is a Trustee of the Ashmolean Museum, Oxford University, a member of the Board of Visitors of the University Library at Cambridge and a member of the Health Advisory Board at Johns Hopkins School of Public Health in Baltimore. He is also a Trustee of the International Institute for Strategic Studies. Recently, he has led the formation of The Blackbird Academy Trust, an academy which has responsibility for three primary schools with 1,250 pupils on the Leys Estate, a part of East Oxford with extensive social problems. He is now Chair of the Academy Board. Chris and his family have homes in Oxford, London and France. Jones became a member of the Lasker Foundation Board in 2014.

Sherry Lansing
During almost 30 years in the motion picture business, Sherry Lansing was involved in the production, marketing, and distribution of more than 200 films, including Academy Award winners Forrest Gump (1994), Braveheart (1995), and Titanic (1997). Throughout her film career, Lansing earned a reputation as a trailblazer, a visionary leader, and a creative filmmaker. In 1980, she became the first woman to head a major film studio when she was appointed President of 20th Century Fox. Later, as an independent producer, Lansing was responsible for such successful films as, Fatal Attraction, The Accused, School Ties, Indecent Proposal, and Black Rain. Returning to the executive ranks in 1992, she was named Chairman and CEO of Paramount Pictures and began an unprecedented tenure that lasted more than 12 years (1992 - 2005), during which the studio enjoyed enormous creative and financial success. The Sherry Lansing Foundation (SLF), a nonprofit organization dedicated to cancer research, health, public education, and encore career opportunities was formed in 2005. Among the SLF's initiatives is the EnCorps Teachers Program, founded by Lansing to retrain retired and mid-career professionals from the technology sector to serve as California public school math and science teachers. Lansing — a former math and English teacher — is also the founder of PrimeTime LAUSD, a partnership with the Los Angeles Unified School District, designed to engage retirees in improving the state of public education through targeted volunteerism. In addition, Lansing serves as Chairman of the University of California Board of Regents. She is also a co-founder of the Big Brothers Big Sisters of Greater Los Angeles Future Fund, which provides college scholarships to deserving "Little Sisters." In December 2004, Lansing was appointed to the Independent Citizens' Oversight Committee of the California Institute for Regenerative Medicine. CIRM was established by California's groundbreaking ballot measure, Proposition 71, which provides $3 billion in funding for embryonic stem cell research. Lansing serves as the cancer patient advocate, as well as Chair of the Governance Committee and Co-Chair of the Scientific and Medical Accountability Standards Working Group. Lansing additionally serves on the boards of the American Association for Cancer Research Foundation, the Carter Center, Encore.org, the Entertainment Industry Foundation, and the W.M. Keck Foundation. She also serves on the Executive Committee of Friends of Cancer Research and lends her energy and talents to the American Red Cross Board of Governors and STOP CANCER, a nonprofit philanthropic group she founded in partnership with the late Dr. Armand Hammer. In addition, Lansing is a co-founder of the Stand Up To Cancer initiative, which funds collaborative, multi-institutional cancer research "Dream Teams." Lansing graduated cum laude with a Bachelor of Science Degree from Northwestern University in 1966.

George P. Noon, MD
George Noon, M.D., is Professor of Surgery and Emeritus, Chief of the Division of Transplant Surgery and Assist Devices in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, Houston, Texas. He serves as Director, Transplant Executive Council for Transplant Services at The Methodist Hospital in Houston; and Director of the Vascular Diagnostic Laboratory at The Methodist Hospital. Additionally, Noon is on the attending staff of The Methodist Hospital. He is also the President of the M.E. DeBakey Medical Foundation. Noon joined the Board of Directors of the Albert and Mary Lasker Foundation in 2010.

George A. Roche
George Roche retired as Chairman and President of T. Rowe Price Group, Inc. in December of 2006 after nearly 39 years with the firm. When Roche joined T. Rowe Price Associates in 1968, he was an analyst covering primarily the natural resources industries. He did much of his work for Mr. Thomas Rowe Price, who started the New Era Fund in 1969. The New Era Fund was designed to invest in inflation resistant companies with an emphasis on natural resources companies. Roche was the President and Portfolio Manager of the New Era Fund from 1979 to 1997. He was also the Chief Financial Officer of T. Rowe Price Associates from 1984 to 1997 and was Chairman and President of T. Rowe Price Group, Inc. from 1997 to 2006. Roche has served on the boards of the Greater Baltimore Committee, Downtown Partnership, The Walters Art Gallery, and McCormick & Co., Inc. He earned a B.A. from Georgetown University and an MBA from Harvard Business School.

Solomon H. Snyder, MD
Born in Washington, D.C. in December 1938, Sol Snyder received his undergraduate and medical training at Georgetown University (MD 1962); Research Associate training with Julius Axelrod at the NIH (1963-1965); and psychiatric training at the Johns Hopkins Hospital (1965-1968). In 1966, he joined the faculty of the Johns Hopkins University School of Medicine (Assistant Professor Pharmacology, 1966-1968; Associate Professor Pharmacology/Psychiatry (1968-1970); Professor (1970). In 1980 he established the Department of Neuroscience and served as Director (1980-2006). He is presently Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry. Snyder is the recipient of numerous professional honors, including the Albert Lasker Award for Basic Biomedical Research (1978), the National Medal of Science (2005); the Albany Medical Prize (2007), Honorary Doctor of Science degrees from Northwestern University (1981), Georgetown University (1986), Ben Gurion University (1990), Albany Medical College (1998), Technion University of Israel (2002), Mount Sinai Medical School (2004), University of Maryland (2006), Charles University, Prague (2009); Ohio State University (2011); the Wolf Foundation Prize in Medicine (1983), the Dickson Prize of the University of Pittsburgh (1983), the Bower Award of the Franklin Institute (1991), the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience Research (1996) and the Gerard Prize of the Society for Neuroscience (2000). He is a member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences and the American Philosophical Society. He is the author of more than 1,000 journal articles and several books.

Alfred Sommer, MD, MHS
Al Sommer is a Gilman Scholar and University Distinguished Service Professor at Johns Hopkins University and Dean Emeritus and Professor of Epidemiology and International Health at the Johns Hopkins Bloomberg School of Public Health, and Professor of Ophthalmology, Johns Hopkins School of Medicine. He was Dean from 1990-2005. Sommer received his MD from Harvard Medical School (1967) and his Master of Health Science in Epidemiology from the Johns Hopkins School of Public Health (1973). He has published 5 books and over 300 scientific articles; has received numerous awards including the Lasker Award for Clinical Medical Research, the Warren Alpert Foundation Prize, and the Duke Elder International Gold Medal for Contributions to Ophthalmology; has delivered over 30 named lectureships, including the Jackson Memorial Lecture (American Academy of Ophthalmology), Duke Elder Oration (Royal College of Ophthalmologists), De Schweinitz Lecture (College of Physicians, Philadelphia), Dohlman Lecture (Harvard Medical School), Doyne Lecture (Oxford Ophthalmologic Congress), and the Kimura Lecture (University of California, San Francisco); and is a member of both the National Academy of Sciences and the Institute of Medicine. His research interests currently include child survival, blindness prevention, and the interface between public health and clinical medicine. Sommer has been a member of the Board of Directors of the Albert and Mary Lasker Foundation since 2004. He was Chairman from 2008 to early 2014.

Russell Steenberg
Russell Steenberg has over 28 years of private equity investment experience. Steenberg is the global head of Private Equity Partners, having joined the Adviser in July 1999 as founder and head of Private Equity Partners. Steenberg is also a member of BlackRock's Leadership Committee. Prior to joining the Adviser, he was a co-founder and Managing Director of Fenway Partners, a middle-market buyout group with $1.4 billion of capital. From 1983 until joining Fenway in 1995, Steenberg was employed by AT&T Investment Management Company, where he was co-head of the AT&T Pension Fund's $3.6 billion private equity investment portfolio. Steenberg currently serves on the advisory boards of the following funds or GPs: SKM Equity Fund III, Quadrangle Capital Partners, Lindsay Goldberg & ;Bessemer, Partech International, Clayton Dubilier & Rice VII, Parallel Investment Partners and THLee VI. In addition, Steenberg is on the Board of Advisors for the Tuck Center of Private Equity and Entrepreneurship, serves on the Board of Westfield Methodist Church and is on the Board of Directors of the Lasker Foundation. Steenberg received his MBA from the Amos Tuck School of Business at Dartmouth College, an MPA from American University, and a BA from St. Lawrence University.

Robert T. Tjian, PhD
Robert Tjian is President of the Howard Hughes Medical Institute, and professor of Molecular and Cell Biology and Director of the Li Ka-Shing Center for Biomedical and Health Science at the University of California, Berkeley. Tjian is a member of several distinguished scientific societies, including the Academia Sinica of China, the National Academy of Sciences, and the American Academy of Arts and Sciences. Tjian serves on Editorial Boards of numerous scientific journals, including Cell, Science, Nature and Genes and Development. Tjian is also on the Advisory Board for the Life Sciences Research Foundation, and is Chair of the Scientific Advisory Board of the Gordon and Betty Moore Foundation. He was on the Board of Trustees of Cold Spring Harbor Laboratory and was a member of the Advisory Board of Overseers at Harvard University. In 1991, Tjian was one of the founders Tularik, which was acquired by Amgen, Inc. in 2004. Tularik had developed a rich pipeline of products in various stages of pre-clinical and clinical studies including therapeutics for cancer, Type 2 diabetes, inflammation, and obesity. Tjian received his Bachelor's Degree in Biochemistry from the University of California at Berkeley and his Ph.D. from Harvard University. Tjian has been a member of the Board of Directors of the Albert and Mary Lasker Foundation since 2008.

Elias A. Zerhouni, MD
Elias Zerhouni served as director the US National Institutes of Health (NIH), the world's foremost biomedical research agency, from 2002 to 2008. During his tenure, Zerhouni promoted many changes at NIH despite challenging budgetary times at the agency. He launched the NIH Roadmap for Medical Research in 2003 to enhance synergy between all 27 NIH Institutes and Centers and to fund compelling initiatives that no single institute could support in both basic and applied research. In addition, Zerhouni launched a series of new programs to encourage high-risk innovative research to enhance interdisciplinary research at the interface of the physical and biological sciences, and to increase support for the independence of early career scientists. During his tenure, NIH tripled its international funding for global health, and it launched comprehensive plans for health disparities, obesity research, and the neurosciences. In 2006, Congress passed the NIH Reform Act, only the third such congressional act since the creation of NIH thus institutionalizing many of his reforms. Prior to joining the NIH, Zerhouni was the Vice Dean for Research and Executive Vice-Dean of the Johns Hopkins University School of Medicine, Chair of the Russell H. Morgan department of Radiology and Radiological Science, and Martin Donner Professor of Radiology, and professor of Biomedical Engineering. Zerhouni, a native of Algeria, immigrated to the US in 1975 at age 24 after earning his medical degree from the University of Algiers School of Medicine. Zerhouni completed his residency in diagnostic radiology at Johns Hopkins as chief resident in the department of Radiology, and joined its faculty to become full professor of Radiology and Biomedical Engineering. His research has focused on pioneering quantitative imaging methods based on CAT and MRI scanning to diagnose and treat cancer, pulmonary, and cardiovascular diseases. He served on the National Cancer Institute's Board of Scientific Advisors from 1998 to 2002, and has been elected a member of the Institute of Medicine of the National Academy of Sciences in 2000. He is also the author of 212 publications and holds 8 patents. Zerhouni joined the Lasker Foundation's Board of Directors in 2009.

Directors Emeriti
Mrs. William McCormick Blair, Jr.
Purnell W. Choppin, MD
Anne B. Fordyce


Chairman Emeritus
James W. Fordyce


Directors Emeriti (in memoriam)
Michael E. DeBakey, MD
Daniel E. Koshland, Jr., PhD